Inimmune is a promising new biotechnology company founded by pharmaceutical industry experts, focused on developing the next generation of vaccines and immunotherapeutics. The group has extensive expertise in synthetic and process chemistry, drug formulation, and immunology. Our pipeline includes innovative new treatments to harness the innate immune system in areas of critical patient need such as oncology, allergic rhinitis, food allergy and infectious disease. Inimmune is fully funded to advance multiple lead programs from pre-clinical to clinical stage in early 2022. We are seeking corporate partnerships for lead programs in oncology, allergy and infectious disease.
Inimmune is presenting as part of the NIH Innovation Zone.